Virtus Fund Advisers’s Biogen BIIB Stock Holding History

Virtus Fund Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$13.3M	Buy	41,890 +1,891	+5%	+$607K	0.13%	165
2017 Q3	$12.5M	Sell	39,999 -11,525	-22%	-$3.41M	0.13%	180
2017 Q2	$14.1M	Sell	51,524 -5,509	-10%	-$1.46M	0.14%	189
2017 Q1	$15.6M	Sell	57,033 -9,180	-14%	-$2.6M	0.15%	184
2016 Q4	$18.8M	Sell	66,213 -2,062	-3%	-$611K	0.16%	171
2016 Q3	$21.4M	Buy	+68,275	New	+$20.2M	0.19%	161
2016 Q2	–	Sell	-63,167	Closed	-$16.4M	–	525
2016 Q1	$16.4M	Buy	63,167 +889	+1%	+$235K	0.15%	179
2015 Q4	$19.1M	Buy	62,278 +184	+0.3%	+$52.9K	0.17%	160
2015 Q3	$18.1M	Sell	62,094 -107	-0.2%	-$35.3K	0.16%	151
2015 Q2	$25.1M	Sell	62,201 -22,685	-27%	-$9.1M	0.19%	148
2015 Q1	$35.8M	Sell	84,886 -10,219	-11%	-$4.03M	0.27%	126
2014 Q4	$32.3M	Sell	95,105 -16,970	-15%	-$5.49M	0.24%	140
2014 Q3	$37.1M	Sell	112,075 -2,592	-2%	-$855K	0.28%	132
2014 Q2	$36.2M	Buy	+114,667	New	+$34.5M	0.25%	150

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Virtus Fund Advisers's BIIB Position: Q4 2017 in Review

Virtus Fund Advisers increased its Biogen (BIIB) stake by 4.7% in Q4 2017, buying an estimated $607K and bringing the position to 41,890 shares worth $13.3M. The position accounts for 0.13% of the portfolio, ranked #165.

Virtus Fund Advisers first reported a position in BIIB in Q2 2014 and has held it in 14 quarters since. The position peaked at $37.1M in Q3 2014. 1,123 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

Virtus Fund Advisers held 41,890 shares of Biogen worth $13.3M as of Q4 2017.
Virtus Fund Advisers bought 1,891 Biogen shares in Q4 2017, an estimated $607K.
Biogen made up 0.13% of Virtus Fund Advisers's portfolio in Q4 2017, its #165 holding.
Virtus Fund Advisers first reported a position in Biogen in Q2 2014 and has held it in 14 quarters since.
Virtus Fund Advisers's Biogen position peaked at $37.1M in Q3 2014.
1,123 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.